Overview Dividends

(CHE) Chemed - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US16359R1032

Hospice, Palliative, Plumbing, Drain, Restoration

Health Care Services
Market Cap in USD: 6,235m
IPO / Inception: 1973-05-03
Return 12m vs S&P 500: -28.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of CHE over the last years for every Quarter: "2020-12": 5.13, "2021-03": 4.44, "2021-06": 4.6, "2021-09": 5.06, "2021-12": 5.25, "2022-03": 4.79, "2022-06": 4.84, "2022-09": 4.74, "2022-12": 5.39, "2023-03": 4.82, "2023-06": 4.71, "2023-09": 5.32, "2023-12": 6.6, "2024-03": 5.2, "2024-06": 5.47, "2024-09": 5.64, "2024-12": 6.83, "2025-03": 5.63, "2025-06": 4.27, "2025-09": 5.27, "2025-12": 0,
EPS CAGR: -46.10%
EPS Trend: -35.5%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of CHE over the last years for every Quarter: 2020-12: 533.289, 2021-03: 527.36, 2021-06: 532.256, 2021-09: 538.667, 2021-12: 540.978, 2022-03: 530.549, 2022-06: 531.288, 2022-09: 526.472, 2022-12: 546.654, 2023-03: 560.157, 2023-06: 553.816, 2023-09: 564.532, 2023-12: 585.912, 2024-03: 589.233, 2024-06: 595.88, 2024-09: 606.181, 2024-12: 639.993, 2025-03: 646.943, 2025-06: 618.798, 2025-09: 624.9, 2025-12: null,
Rev. CAGR: 3.92%
Rev. Trend: 94.7%
Last SUE: -0.14
Qual. Beats: 0

Dividends

Dividend Yield 0.49%
Yield on Cost 5y 0.41%
Yield CAGR 5y 11.96%
Payout Consistency 96.1%
Payout Ratio 10.0%
Risk via 5d forecast
Volatility 26.9%
Value at Risk 5%th 37.0%
Relative Tail Risk -16.31%
Reward TTM
Sharpe Ratio -0.52
Alpha -22.00
CAGR/Max DD -0.07
Character TTM
Hurst Exponent 0.243
Beta 0.258
Beta Downside 0.071
Drawdowns 3y
Max DD 36.37%
Mean DD 12.30%
Median DD 10.48%

Description: CHE Chemed January 09, 2026

Chemed Corp (NYSE:CHE) operates two distinct businesses: VITAS, the nation’s largest hospice and palliative-care provider, and Roto-Rooter, a leading residential and commercial plumbing and water-damage-restoration franchise. The firm delivers clinical services-including nursing, social work, and spiritual counseling-to patients and families across the U.S., while Roto-Rooter generates revenue through company-owned branches, independent contractors, and franchisees offering plumbing, drain cleaning, excavation, and water-restoration services.

Key drivers to watch: (1) VITAS’s revenue has grown at a 7% CAGR over the past three years, supported by an aging U.S. population and increasing Medicare enrollment for hospice care; (2) Roto-Rooter contributes roughly 45% of total consolidated revenue and benefits from rising home-ownership rates and heightened consumer spending on home-maintenance services; (3) Chemed’s adjusted EBITDA margin hovers around 16%-above the industry median of ~13%-reflecting operational efficiencies and franchise-model scalability. However, the company remains exposed to Medicare reimbursement policy changes and labor-cost pressures in both segments.

For a deeper dive into CHE’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (278.8m TTM) > 0 and > 6% of Revenue (6% = 151.8m TTM)
FCFTA 0.22 (>2.0%) and ΔFCFTA 4.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 4.08% (prev 9.49%; Δ -5.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.26 (>3.0%) and CFO 419.7m > Net Income 278.8m (YES >=105%, WARN >=100%)
Net Debt (11.7m) to EBITDA (438.1m) ratio: 0.03 <= 3.0 (WARN <= 3.5)
Current Ratio 1.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (14.5m) change vs 12m ago -3.63% (target <= -2.0% for YES)
Gross Margin 32.24% (prev 35.66%; Δ -3.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 149.2% (prev 134.3%; Δ 14.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 114.2 (EBITDA TTM 438.1m / Interest Expense TTM 3.27m) >= 6 (WARN >= 3)

Altman Z'' 13.31

(A) 0.06 = (Total Current Assets 395.2m - Total Current Liabilities 292.0m) / Total Assets 1.62b
(B) 1.78 = Retained Earnings (Balance) 2.89b / Total Assets 1.62b
warn (B) unusual magnitude: 1.78 — check mapping/units
(C) 0.22 = EBIT TTM 373.7m / Avg Total Assets 1.70b
(D) 5.35 = Book Value of Equity 2.93b / Total Liabilities 546.9m
Total Rating: 13.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.80

1. Piotroski 8.50pt
2. FCF Yield 5.77%
3. FCF Margin 14.24%
4. Debt/Equity 0.13
5. Debt/Ebitda 0.03
6. ROIC - WACC (= 18.29)%
7. RoE 24.37%
8. Rev. Trend 94.74%
9. EPS Trend -35.52%

What is the price of CHE shares?

As of January 09, 2026, the stock is trading at USD 449.18 with a total of 217,980 shares traded.
Over the past week, the price has changed by +5.99%, over one month by +8.89%, over three months by +3.41% and over the past year by -15.19%.

Is CHE a buy, sell or hold?

Chemed has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CHE.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CHE price?

Issuer Target Up/Down from current
Wallstreet Target Price 574.3 27.8%
Analysts Target Price 574.3 27.8%
ValueRay Target Price 437.3 -2.6%

CHE Fundamental Data Overview January 02, 2026

P/E Trailing = 22.7827
P/E Forward = 17.0358
P/S = 2.4637
P/B = 5.6455
P/EG = 1.7022
Beta = 0.462
Revenue TTM = 2.53b USD
EBIT TTM = 373.7m USD
EBITDA TTM = 438.1m USD
Long Term Debt = 141.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 42.0m USD (from shortTermDebt, last quarter)
Debt = 141.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.7m USD (from netDebt column, last quarter)
Enterprise Value = 6.25b USD (6.23b + Debt 141.5m - CCE 129.8m)
Interest Coverage Ratio = 114.2 (Ebit TTM 373.7m / Interest Expense TTM 3.27m)
FCF Yield = 5.77% (FCF TTM 360.4m / Enterprise Value 6.25b)
FCF Margin = 14.24% (FCF TTM 360.4m / Revenue TTM 2.53b)
Net Margin = 11.02% (Net Income TTM 278.8m / Revenue TTM 2.53b)
Gross Margin = 32.24% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Gross Margin QoQ = 28.91% (prev 29.85%)
Tobins Q-Ratio = 3.85 (Enterprise Value 6.25b / Total Assets 1.62b)
Interest Expense / Debt = 1.41% (Interest Expense 2.00m / Debt 141.5m)
Taxrate = 23.11% (19.3m / 83.5m)
NOPAT = 287.4m (EBIT 373.7m * (1 - 23.11%))
Current Ratio = 1.35 (Total Current Assets 395.2m / Total Current Liabilities 292.0m)
Debt / Equity = 0.13 (Debt 141.5m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 0.03 (Net Debt 11.7m / EBITDA 438.1m)
Debt / FCF = 0.03 (Net Debt 11.7m / FCF TTM 360.4m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.43% (Net Income 278.8m / Total Assets 1.62b)
RoE = 24.37% (Net Income TTM 278.8m / Total Stockholder Equity 1.14b)
RoCE = 29.07% (EBIT 373.7m / Capital Employed (Equity 1.14b + L.T.Debt 141.5m))
RoIC = 25.12% (NOPAT 287.4m / Invested Capital 1.14b)
WACC = 6.83% (E(6.23b)/V(6.38b) * Re(6.96%) + D(141.5m)/V(6.38b) * Rd(1.41%) * (1-Tc(0.23)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.44%
[DCF Debug] Terminal Value 84.08% ; FCFF base≈341.3m ; Y1≈376.4m ; Y5≈485.5m
Fair Price DCF = 790.3 (EV 11.16b - Net Debt 11.7m = Equity 11.15b / Shares 14.1m; r=6.83% [WACC]; 5y FCF grow 11.79% → 3.0% )
EPS Correlation: -35.52 | EPS CAGR: -46.10% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.74 | Revenue CAGR: 3.92% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=5.99 | Chg30d=+0.073 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=25.48 | Chg30d=+0.160 | Revisions Net=+2 | Growth EPS=+14.8% | Growth Revenue=+6.2%

Additional Sources for CHE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle